atai Life Sciences Acquires Majority Stake in Recognify Life Sciences to Develop Novel Treatment for Cognitive Impairment Associated with Schizophrenia

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it has acquired a majority stake in Recognify Life Sciences, an entity developing a treatment for Cognitive Impairment associated with Schizophrenia (CIAS). Recognify’s lead compound, “RL-007”, previously called FSV7-007, has exhibited a modulating effect on three mechanisms that are central to learning and memory: the cholinergic, NMDA and GABA type B receptor systems.